Commence the filing of a Biologics License Application for deramiocel
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 24 Sep 2024
- Due
- 31 Oct 2024
- Delivered
- October 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Capricor plans to commence the filing of a BLA in October of 2024”
What we found
Evidence strength A What the grades mean
The company initiated the rolling Biologics License Application (BLA) submission for deramiocel in October 2024, as confirmed by multiple SEC filings.
-
A Capricor Therapeutics, Inc. 8-K filed 2024-11-13
“Rolling BLA submission initiated in October 2024” ✓ confirmed on the page
-
A Capricor Therapeutics, Inc. 10-Q filed 2024-11-14
“We initiated the BLA filing in October of 2024” ✓ confirmed on the page
Market reaction: the shares moved +4.7% against the S&P 500 over the three sessions around the disclosure (12 Nov 2024 to 15 Nov 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 24 Sep 2024
Deadline 31 Oct 2024 (“October of 2024”) · wording expected
-
Version 2 · stated 11 Jul 2025
Deadline 30 Sep 2025 (“in Q3 2025”) · wording aspirational
“Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Commence
- Deliverable
- Biologics License Application
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-CAPR-002554 · Corrections policy